JNJ,PFE -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • With stocks like FB or P&G, check your bias at the door
    CNBC Videos6 hours ago

    With stocks like FB or P&G, check your bias at the door

    Jim Cramer argued against selling high-quality stocks because of negative news and told investors to break the weak-handed habit.

  • Cramer: Check your bias at the door with stocks like Face...
    CNBC Videos7 hours ago

    Cramer: Check your bias at the door with stocks like Face...

    Jim Cramer argued against selling high-quality stocks because of negative news and told investors to break the weak-handed habit.

  • The Wall Street Journal56 minutes ago

    [$$] Johnson & Johnson Results Driven by Pharmaceutical Sales Growth

    Johnson & Johnson reported an increase in sales for its fourth quarter, largely spurred by its pharmaceutical business, but reported a loss because of effects from the new tax law.

  • Stocks Flatline as VIX Remains Buoyant
    InvestorPlace8 hours ago

    Stocks Flatline as VIX Remains Buoyant

    U.S. stocks finished mixed on Tuesday as relief over the reopening of the government has given way to new apprehension about looming budget and immigration talks. The debt ceiling looming large in late February has added fuel to the mix-up and increased the stakes.

  • TheStreet.com9 hours ago

    Dow Closes Wild Tuesday on Sour Note

    Stocks are mixed on Tuesday as investors turn their attention to corporate earnings.

  • Associated Press9 hours ago

    Netflix and Whirlpool jump while Twitter and J&J fall

    Stocks that moved substantially or traded heavily on Tuesday: Netflix Inc., up $22.71 to $250.29 The streaming video service gained more subscribers than industry watchers had expected in its latest quarter. ...

  • Johnson & Johnson loses $10.7B after sweeping US tax changes
    Associated Press9 hours ago

    Johnson & Johnson loses $10.7B after sweeping US tax changes

    Johnson & Johnson posted a rare quarterly loss, a whopping $10.71 billion, due to a $13.6 billion charge related to last month's U.S. tax overhaul.

  • Forbes9 hours ago

    Where's The Tylenol? J&J Disappoints And Frustrates

    Shares of J&J were hammered today after the health-care giant delivered consensus-beating fourth quarter financial results and full-year 2018 guidance. The numbers below the surface chased off investors. Here’s why.

  • Reuters9 hours ago

    Netflix lifts S&P, Nasdaq; J&J, Procter hold Dow in check

    U.S. stocks advanced on Tuesday, as strong results from Netflix helped lift the S&P and Nasdaq Composite, but the Dow Industrials were hemmed in by declines in Johnson & Johnson and Procter & Gamble. Netflix touched a record high of $257.71 and was last up 9.98 percent at $250.29, to cross the $100 billion market value threshold. The video-streaming pioneer beat Wall Street targets for new subscribers in the fourth quarter.

  • Associated Press9 hours ago

    Markets Right Now: Tech stocks send indexes mostly higher

    NEW YORK (AP) — The latest on developments in financial markets (All times local):

  • Reuters11 hours ago

    U.S. appeals court upholds ruling invalidating J&J patent on Remicade

    The U.S. Circuit Court of Appeals for the Federal Circuit affirmed a ruling by a U.S. administrative court that a J&J patent covering the active ingredient in Remicade was invalid because its concepts were covered in a prior J&J patent. Remicade generated U.S. sales of $4.8 billion for J&J in 2016 but it faces increased competition from cheaper "biosimilar" copycats, including Pfizer's version, which is sold in the United States under the name Inflectra.

  • Reuters11 hours ago

    J&J takes $13.6 billion charge related to new U.S. tax law

    Also on Tuesday, U.S. appeals court upheld a ruling that invalidated a crucial J&J patent on its blockbuster rheumatoid arthritis drug Remicade. U.S. President Donald Trump signed the new U.S. tax law late last year, and many large U.S. corporations and drugmakers have said they will take advantage of its new, lower tax rate on repatriated foreign earnings and cash. J&J reported a year ago that it had $66 billion in undistributed international earnings and on Tuesday said it had $16 billion in cash outside the United States.

  • Reuters11 hours ago

    U.S. appeals court upholds ruling invalidating J&J patent on Remicade

    A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug. The U.S. Circuit Court of Appeals for the Federal Circuit affirmed a ruling by a U.S. administrative court that a J&J patent covering the active ingredient in Remicade was invalid because its concepts were covered in a prior J&J patent.

  • CNBC11 hours ago

    The new tax law won't change Johnson & Johnson's M&A strategy, CEO says

    Johnson & Johnson took hit from the new tax law but will see a lower effective rate because of the changes.

  • CNBC12 hours ago

    Johnson & Johnson's guidance impresses before 'disappointing'

    Johnson & Johnson shares slipped Tuesday after the company clarified its forecast for the year.

  • Barrons.com12 hours ago

    Johnson & Johnson Earnings: When Strong Isn't Strong Enough

    Not much has changed for the health-care conglomerate, analysts said, but there was enough for investors to take some profits. “In this market, a company—not just J&J—needs to deliver clean, perfect quarterly results and guides, not just on the headline number but everything that goes into it,” Glenn Novarro, an analyst at RBC Capital Markets, tells Barron’s. He still has an outperform rating on the stock.

  • Reuters12 hours ago

    Johnson & Johnson takes $13.6 billion charge related to new U.S. tax law

    Also on Tuesday, U.S. appeals court upheld a ruling that invalidated a crucial J&J patent on its blockbuster rheumatoid arthritis drug Remicade. U.S. President Donald Trump signed the new U.S. tax law late last year, and many large U.S. corporations and drugmakers have said they will take advantage of its new, lower tax rate on repatriated foreign earnings and cash. J&J reported a year ago that it had $66 billion in undistributed international earnings and on Tuesday said it had $16 billion in cash outside the United States.

  • Reuters12 hours ago

    J&J takes $13.6 bln charge related to new U.S. tax law

    Healthcare conglomerate Johnson & Johnson on Tuesday took a $13.6-billion charge related to the new U.S. tax law and plans to bring back billions of dollars from overseas immediately. The company, based in New Brunswick, New Jersey, plans to move $12 billion of that cash immediately, J&J CFO Dominic Caruso said during a conference call with analysts, and will be used to fund U.S. operations, primarily by paying down debt.

  • CNBC12 hours ago

    The US is in a baby bust, so diaper makers need a new plan

    The declining birth rate in the U.S. is hurting some of the country's biggest consumer companies.

  • Can Intuitive Surgical Beat Analyst Estimates Again in 4Q17?
    Market Realist13 hours ago

    Can Intuitive Surgical Beat Analyst Estimates Again in 4Q17?

    Intuitive Surgical: Why It's Expected to Post Strong 4Q17 ResultsEarnings announcement and preliminary results

  • Johnson & Johnson Shares Fall Despite Earnings Beat
    GuruFocus.com13 hours ago

    Johnson & Johnson Shares Fall Despite Earnings Beat

    Company records charge related to tax reform

  • Don't Expect a Huge J&J Investment Surge
    Bloomberg13 hours ago

    Don't Expect a Huge J&J Investment Surge

    Its tax-cut windfall will more likely go to dividends and buybacks.

  • Johnson & Johnson Stock Dips Despite Q4 Earnings Beat
    InvestorPlace13 hours ago

    Johnson & Johnson Stock Dips Despite Q4 Earnings Beat

    This is an increase from its earnings per share of $1.58 from the same time last year. It also beat out Wall Street’s earnings per share estimate of $1.72 for the period, but couldn’t save JNJ stock today. Revenue reported by Johnson & Johnson for the fourth quarter of 2017 was $20.20 billion.

  • JNJ, PG, TRV, KMB Post Q4 Earnings
    Zacks14 hours ago

    JNJ, PG, TRV, KMB Post Q4 Earnings

    JNJ, PG, TRV, KMB Post Q4 Earnings

  • Reuters14 hours ago

    Drug companies told to do more to tackle 'superbug' crisis

    Drugmakers' response to the threat posed by "superbugs" remains patchy even after years of warnings, according to the first analysis of individual companies' efforts to tackle the antibiotic resistance crisis. The rise of drug-resistant bacteria is a growing threat to modern medicine with the emergence of infections resistant to even last-resort antibiotics - a situation made worse in recent years by overuse of antibiotics and cutbacks in drug research. New analysis by the non-profit Access to Medicine Foundation (AMF), published on Tuesday, found that GlaxoSmithKline (GSK.L) and Johnson & Johnson (JNJ.N) were doing more than most among large research-based pharmaceutical companies to tackle the problem, while Mylan (MYL.O) led the way among generic drugmakers and Entasis was top among biotechs.